Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Sutro Biopharma Inc is a biotechnology business based in the US. Sutro Biopharma shares (STRO) are listed on the NASDAQ and all prices are listed in US Dollars. Sutro Biopharma employs 218 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $10.07 |
|---|---|
| 52-week range | $9.62 - $28.30 |
| 50-day moving average | $15.97 |
| 200-day moving average | $18.46 |
| Wall St. target price | $31.50 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.85 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $10.07 from 2022-01-21
| 1 week (2022-01-14) | -5.89% |
|---|---|
| 1 month (2021-12-22) | -31.50% |
| 3 months (2021-10-22) | -47.03% |
| 6 months (2021-07-23) | -40.97% |
| 1 year (2021-01-22) | -63.44% |
|---|---|
| 2 years (2020-01-24) | -9.36% |
| 3 years (2019-01-24) | 10.17 |
| 5 years (2017-01-20) | N/A |
| Revenue TTM | $59.5 million |
|---|---|
| Gross profit TTM | $-34,239,000 |
| Return on assets TTM | -15.71% |
| Return on equity TTM | -48.12% |
| Profit margin | -213.36% |
| Book value | $6.13 |
| Market capitalisation | $495.1 million |
TTM: trailing 12 months
We're not expecting Sutro Biopharma to pay a dividend over the next 12 months.
Over the last 12 months, Sutro Biopharma's shares have ranged in value from as little as $9.62 up to $28.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sutro Biopharma's is 0.804. This would suggest that Sutro Biopharma's shares are less volatile than average (for this exchange).
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.